Novel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine diphosphate-ribose) polymerase inhibition

M William Audeh

Division of Medical Oncology, Samuel Oschin Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA

Abstract: Inhibitors of the poly(adenosine triphosphate-ribose) polymerase (PARP)-1 enzyme induce synthetic lethality in cancers with ineffective DNA (DNA) repair or homologous repair deficiency, and have shown promising clinical activity in cancers deficient in DNA repair due to germline mutation in BRCA1 and BRCA2. The majority of breast cancers arising in carriers of BRCA1 germ-line mutations, as well as half of those in BRCA2 carriers, are classified as triple-negative breast cancer (TNBC). TNBC is a biologically heterogeneous group of breast cancers characterized by the lack of immunohistochemical expression of the ER, PR, or HER2 proteins, and for which the current standard of care in systemic therapy is cytotoxic chemotherapy. Many “sporadic” cases of TNBC appear to have indicators of DNA repair dysfunction similar to those in BRCA-mutation carriers, suggesting the possible utility of PARP inhibitors in a subset of TNBC. Significant genetic heterogeneity has been observed within the TNBC cohort, creating challenges for interpretation of prior clinical trial data, and for the design of future clinical trials. Several PARP inhibitors are currently in clinical development in BRCA-mutated breast cancer. The use of PARP inhibitors in TNBC without BRCA mutation will require biomarkers that identify cancers with homologous repair deficiency in order to select patients likely to respond. Beyond mutations in the BRCA genes, dysfunction in other genes that interact with the homologous repair pathway may offer opportunities to induce synthetic lethality when combined with PARP inhibition.

Keywords: PARP, triple negative breast cancer, PARP inhibitors

Introduction

Breast cancers defined by the lack of demonstrable expression of the ER, PR, or HER2 proteins represent approximately 15%–20% of all breast cancers, and have been labeled “triple-negative” breast cancers (TNBCs), although they do not truly represent a homogeneous group with biologically uniform behavior. Classic morphologic descriptions by light microscopy and simple immunohistochemistry have led to the identification of this subset as TNBC for clinical utility, facilitating the assumption that they represent a discrete clinical entity. While clinical case series and reviews have indeed identified a generally poor prognosis for these cancers in comparison to ER-positive and HER2-positive cancers, owing in large part to the absence of effective targeted therapies with broad activity in breast cancers defined only as TNBC. However, significant biological diversity exists within this subgroup, as revealed by molecular analysis on a variety of platforms. It is this biological diversity within the TNBC subset that now directs the design of clinical trials, as targets identified within subsets of TNBC have led to trials utilizing targeted therapies in sensitive subsets defined by the presence of...
predictive biomarkers. One such targeted therapy of interest in the treatment of TNBC is the family of compounds capable of inhibiting the poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) enzyme. By inhibiting primarily PARP-1 and -2, PARP inhibitors currently undergoing investigation induce a number of biological effects, most importantly the inhibition of the deoxyribo nucleic acid (DNA)-repair pathway involved in base-excision repair (BER). The basis for considering PARP inhibitors as potential therapies for TNBC and the challenges encountered and expected in the application of PARP inhibitors in the TNBC population are the subject of this review.

**Redefining TNBC based on meaningful biology**

TNBCs have been identified and defined in routine clinical practice by the absence of immunohistochemical staining for three proteins: ER, PR, and HER2. The further definition of breast cancer by gene-expression patterns based on messenger ribonucleic acid (mRNA) rather than protein yielded the intrinsic molecular subtypes luminal A, luminal B, HER2-enriched, and basal type.²⁻⁷ TNBC was assumed to fall within the basal subtype, as they share the absence of immunohistochemical markers; however, considerable evidence has shown that not all TNBCs are truly basal by gene expression.⁸⁻¹⁰ Molecular analysis of TNBC cohorts by a variety of platforms, including microarray, DNA copy-number variation, and DNA sequencing,⁵,¹⁰,¹¹ reveal that approximately 20%–25% of TNBCs do not display basal breast cancer genomic markers, and conversely between 25% and 30% of basal breast cancers defined genomically do not show TNBC immunohistochemistry. Therefore, not all TNBCs defined by immunohistochemistry will be basal breast cancers, as defined by genomic profiling. More importantly, these findings call into question the validity of utilizing targeted therapies in cohorts of breast cancer defined simply as TNBC¹² without further molecular stratification, and should perhaps lead to reconsideration of therapies that have produced negative results in such unselected trial populations.

Within the TNBC cohort, significant biological diversity exists as well, resulting in variability of clinical outcomes in response to chemotherapy.¹³,¹⁴ Lehmann et al¹¹ identified six defined subtypes within a cohort of TNBC based on gene expression, identified as basal-like (BL)-1, BL2, mesenchymal, mesenchymal stem-like (MSL), immunomodulatory, and luminal androgen receptor (LAR). Genomic cluster analysis identified specific genes and pathways characterizing these subsets, such as proliferative and DNA-repair pathways in BL1; EGF, MET and Wnt in BL2; immune signaling in immunomodulatory; cell motility in both mesenchymal and mesenchymal stem-like; and hormonal signaling in the luminal androgen receptor. Significant clinical diversity between these robustly defined molecular subtypes was observed, as evidenced by markedly different responsiveness to neoadjuvant chemotherapy: 52% pathologic complete remission (pCR) in BL1, and 0 pCR in BL2, for example.¹⁵ A meta-analysis of gene expression in 190 TNBCs identified by immunohistochemistry and also identified as BL by the intrinsic gene set, also revealed considerable clinical diversity in prognosis, with signatures of an activated stroma showing a poorer prognosis, while signatures reflecting BRCA1 loss, reduced mTOR signaling, and an activated Src pathway were associated with a better prognosis.

The most common aspect of biology within the TNBC cohort, identified by the Cancer Genome Atlas Network,⁵ appears to be mutation or deletion of TP53, observed in 71%. (The prevalence of mutations in TP53 or related pathway members rose to nearly 100% when limited to BL cancers.) The high frequency of p53 dysfunction in TNBC does unite this group as having significant genomic instability, likely due to some defect in DNA-repair proficiency.

The best-known such defect in DNA repair in TNBC is due to mutation in BRCA1 or BRCA2, and is associated with germ-line inheritance. Over 2,000 different mutations have been identified in BRCA1 and BRCA2, with most being deletions or insertions, as well as single-nucleotide substitutions, in both coding and noncoding sequences.¹⁶ Most mutations result in frameshift, truncation, and splice-site changes leading to protein dysfunction, and large genomic rearrangements, particularly in BRCA1, are also frequent. While copy-number variation is not typical in germ-line BRCA1 and BRCA2 mutations, somatic loss of heterozygosity is a frequent consequence of loss of BRCA function.

The prevalence of BRCA1 or BRCA2 germ-line mutation in breast cancer in general is estimated to be 5%–10%, while in TNBC the prevalence has been assessed as between 10.6% and 19.8%.¹⁷,¹⁸ However, 75%–80% of cancers arising in BRCA1 carriers and approximately 50% of those in BRCA2 carriers are TNBC.¹⁹ As will be discussed in this paper, the DNA-repair defect in BRCA-mutated cancers, primarily affecting double-strand break repair through homologous recombination, places increased dependence on the proficiency of base-excision repair, and therefore the function of PARP, in these cancers. Inhibition of PARP function in BRCA-mutated cancers leads to cell death,²⁰,²¹ and has
led to numerous clinical trials with PARP inhibitors in this population. The characteristic genomic instability common to both BRCA1-mutated cancers and TNBC in general has been termed “BRCAness”, and forms the basis for the interest in TNBC as a potential target for PARP inhibitors.

BRCAness has been characterized in a number of ways, beginning with extreme genomic instability, a high frequency of TP53 mutations, loss of RAD51-focus formation, and sensitivity to DNA cross-linking agents, as well as BRCA4-like array comparative genomic hybridization, and presumed markers of DNA-repair proficiency, such as RAD51 functionality, PARP-1 expression levels, and other BER-pathway members. To the extent that homologous repair deficiency (HRD) is considered essential for BRCAness, HRD assays have also been investigated in TNBC.

Somatic inactivation of BRCA1 by promoter hypermethylation occurs in approximately 15% of all sporadic breast cancers, and in TNBC the frequency is as high as 27%–37%. The majority of BRCA1-methylated cancers display a BRCAness profile defined by a BRCA1-like or BRCA2-like comparative genomic hybridization assay. However, the biological effects of somatic inactivation of BRCA1 are not entirely equivalent to the effects of a germ-line BRCA1 mutation, as evidenced by different responsiveness to standard neoadjuvant chemotherapy, with a 63% pCR observed in germ-line BRCA1 and 35% pCR in cancers with somatic inactivation of BRCA1. Nevertheless, cancers lacking a germ-line BRCA mutation but displaying BRCAness do have similar clinical features, including younger age of onset, apparent dysfunction of homologous DNA repair, and possibly increased sensitivity to platinum chemotherapy.

Therefore, a substantial proportion of TNBCs possess some form of BRCA dysfunction by either germ-line or somatic inactivation of BRCA1 or BRCA2, and those that do not may still harbor other defects in DNA repair leading to HRD, and producing characteristic genomic instability, high frequency of p53-pathway dysfunction, and as a result possible sensitivity to PARP inhibition. This direction of clinical research is however complicated by the imprecision of defining clinical cohorts by TNBC status alone, and by the challenges of defining BRCAness in cancers lacking a known BRCA germ-line mutation, a cohort that makes up the majority of TNBC.

Targeting poly(ADP-ribose) polymerase with PARP inhibitors

The PARP family of enzymes, first described in 1963, encompasses 17 enzymes, six of which utilize nicotinamide adenine dinucleotide (NAD⁺) as the substrate to synthesize polymeric chains of ADP-ribose for the purpose of post-translational modification of target proteins. Of these, PARP-1 is the primary enzyme involved in the regulation of DNA repair, although PARP-2 and PARP-3 are also involved to a lesser extent. PARP-1 is a nuclear protein with two zinc-finger domains that bind to areas of single-strand DNA breaks within seconds of the damage, and initiates the formation of a poly-ADP scaffold that recruits other members of the BER pathway, such as XRCC1. The BER pathway is not essential for cellular survival and the ultimate repair of stalled replication forks and double-strand breaks in HR-proficient cells. However, in the absence of BRCA1 or BRCA2 function, double-strand break repair through homologous recombination is impaired; the loss of BER through PARP inhibition in such cells produces catastrophic genomic instability and cell death. This synergy between the intrinsic HRD caused by the loss of BRCA function and the induced loss of BER function through PARP inhibition has been termed “synthetic lethality”. The intense recent interest in PARP inhibition as a form of cancer therapy was promoted by the observation of significant cell death in BRCA-deficient cell lines treated only with a PARP inhibitor in the absence of any other DNA-damaging agents. The intrinsic sensitivity of BRCA-mutated cancer to PARP inhibition was thus established, and led to the clinical development of several compounds believed to be PARP inhibitors. (See Table 1 for a timeline of PARP-inhibitor development.)

Inhibitors of PARP-1 were initially discovered over 30 years ago, and the original molecular structure formed the basis for the development of PARP inhibitors currently in clinical trials, utilizing nicotinamide-like scaffolds with modified side-chain groups. Inhibition of the PARP-1 and PARP-2 enzymes is thought to be achieved primarily through small-molecule binding to the catalytic domain that binds NAD⁺. However, the effect of the PARP-inhibitor side chain extending outside the NAD catalytic site may also be to “trap”...
the PARP enzyme at the site of DNA damage, preventing its usual release from the DNA molecule.38-40 “PARP trapping” may therefore be an additional action of some PARP inhibitors that may contribute to their potential cytotoxicity. In response to the presence of single-strand DNA breaks, PARP-1 binds to the damaged site through its zinc-finger domains. This binding activates the catalytic activity of PARP-1, and the initiation of poly(ADP) polymerization. This produces not only a poly(ADP) scaffold that recruits and binds other DNA-repair proteins but also adds poly(ADP) moieties to PARP-1 itself, leading under normal cell physiology to an increasingly negative charge on the enzyme, and eventual dissociation from the DNA.

While the preclinical data suggested the requirement for HRD as mediated through loss of BRCA function for sensitivity to PARP inhibition, interest was also generated in utilizing PARP inhibition in association with the induction of DNA damage by chemotherapy in the more general cohort of TNBC, regardless of BRCA-mutation status.41 Unfortunately, this initial approach utilized the agent BSI-201, or iniparib, a molecule thought to be a PARP inhibitor, but which was ultimately found to be lacking PARP-1- and -2-inhibitor activity.42 Prior to the reporting of a lack of PARP-inhibitory activity, however, two large and highly publicized trials with iniparib in TNBC were undertaken, and nearly put an end to the development of PARP inhibitors in cancer therapy.43

**Clinical trials with iniparib in triple-negative breast cancer – a false start for PARP inhibitors**

Iniparib was initially developed as a PARP inhibitor, and showed evidence of PARP inhibition in peripheral blood mononuclear cells by over 50% after a single dose in a Phase I trial.42 However, no other biomarkers of PARP inhibition, such as induction of γ-H2AX foci, were reported, and the chemical structure of the compound was not revealed to consultants knowledgeable in the chemistry of PARP inhibitors.43 A randomized, open-label Phase II trial combining iniparib with chemotherapy, carboplatinum, and gemcitabine, versus chemotherapy alone, in 123 women with metastatic TNBC was reported at the 2009 American Society of Clinical Oncology Meeting, and subsequently published.44 The BRCA status of the trial participants was not reported; however, the response rate rose from 32% to 52% with the addition of iniparib, and improvements in both progression-free (3.6 months versus 5.9 months) and overall survival (7.7 months to 12.3 months) were reported. Based on the significantly positive results, a Phase III trial with the same design was immediately conducted. Within 1 month of the publication of the Phase II results, the sponsors of the trial reported that the Phase III trial had failed to confirm the Phase II results, with no difference between the control arm and the iniparib arm.45

The failure of the iniparib Phase III trial to meet its end point was initially believed to indicate a lack of efficacy of PARP-inhibitor therapy in TNBC, until definitive in vitro cellular assays for functional PARP inhibition revealed that iniparib did not significantly inhibit PARP-1 or PARP-2 catalytic activity, and could not be classified as a PARP inhibitor.44 While initial preclinical observations of PARP-1 enzyme inhibition by metabolites of iniparib were made in cell-free systems, three functional cell-based assays were used to compare iniparib to two known PARP inhibitors with chemical structures quite different from iniparib: olaparib and veliparib.37 The assays compared 1) selective induction of apoptosis or inhibition of colony formation in HR-deficient cell lines with BRCA2 or ATM mutations, 2) selective sensitization of HR-proficient cells to topoisomerase I poisons, and 3) inhibition of the formation of poly(ADP-ribose) polymer (pADPr) in intact cells. In contrast to the distinct activity of olaparib and veliparib in these assays, iniparib exhibited little or no ability to selectively kill HR-deficient cells, sensitize cells to topoisomerase I poisons, or inhibit pADPr formation in intact cells. Although iniparib did display cytotoxicity in normal and neoplastic cells at high (>40 µmol/L) concentrations, its mechanism of action appeared unlikely to be via PARP inhibition. While these and similar findings45,46 put to rest the development of iniparib as a PARP inhibitor, they also led to renewed interest in true PARP inhibitors as active therapeutic single agents, or in combination with chemotherapy, in tumors with identifiable HRD, such as germ-line BRCA mutations.46 PARP inhibitors have been studied in clinical trials in ovarian cancer and breast cancer47,48 and a number of other tumor types,49 with activity mainly in individuals with known germ-line BRCA mutations,48 although there is a rationale for use in cancers assumed to have somatically acquired HRD, such as TNBC without germ-line BRCA mutation.

**Clinical trials with PARP inhibitors in breast cancer and the rationale for use in TNBC**

A number of early phase clinical trials have assessed the activity of PARP inhibitors in cohorts of patients that included or were limited to breast cancer. These trials utilized PARP inhibitors either as single agents, attempting to elicit
synthetic lethality in sensitive cohorts, or in combination with chemotherapy, where the action of PARP inhibition as a chemosensitizer cannot be readily separated from any element of synthetic lethality. While most responses have been seen in patients with *BRCA* germ-line mutations, with often significant and long-lasting clinical benefit, the broad early clinical experience with a variety of PARP inhibitors has led to intense clinical research interest in expanding the population of patients potentially sensitive to PARP inhibition, including TNBC. The available data on PARP inhibitors in breast cancer is summarized in the following sections.

**Olaparib (AZD 2811)**

Olaparib, formerly known as AZD 2811, has been the PARP inhibitor most extensively studied in breast cancer to date (if one excludes iniparib for the reasons described earlier). A Phase I study in human subjects was conducted with olaparib beginning in 2005, and enriched for patients with *BRCA* germ-line mutations. Of the 60 patients in the trial, objective responses were only seen among the 22 who were known *BRCA* carriers. Of the nine breast cancer patients (molecular subtype not specified) in this trial, three had *BRCA*2 mutations, two of whom had objective responses, including a complete remission lasting over 60 weeks.

The Phase I trial was followed by one of the two largest trials thus far of a PARP inhibitor in breast cancer. A Phase II trial of olaparib as a single agent enrolled 54 patients with germ-line *BRCA* mutations and metastatic breast cancer previously treated with a median of three prior chemotherapy regimens, as reported by Tutt et al. Two dose cohorts were studied, and 29 of those enrolled had TNBC. Of the 13 TNBC patients in the higher-dose cohort, seven of 13 (54%) showed a partial response, and four of 13 (31%) had stable disease; however, even in the lower-dose cohort, four of 16 (25%) TNBC patients showed a partial response, and seven of 16 (44%) had stable disease. Responses were not limited to TNBC, however, and the objective response rate for the entire higher-dose cohort, which included ER-positive and HER2-positive patients was 41%, with a median progression-free survival of nearly 6 months. The conclusion of this trial was that responsiveness to PARP inhibition in breast cancer was not a feature of TNBC but of *BRCA*-mutated breast cancer.

A more recent trial of olaparib in nearly 300 patients with a variety of *BRCA*-mutated cancers was reported at the American Society of Clinical Oncology Meeting in 2013 by Kaufman et al, and included 62 patients with breast cancer. Eight of 62, or 12.9%, had an objective response, with disease stabilization in 47%. The lower response rate than the prior trial may be explained by the fact that this cohort was more heavily pretreated than in the Tutt et al trial, with the mean number of prior chemotherapies for metastatic disease being 4.6. More importantly, 47.6% (20 of 42) of patients had received prior platinum (including 26% cisplatin and 45% carboplatin), a factor that may predict resistance to PARP-inhibitor therapy.

In contrast to the response rates seen in the Tutt et al and Kaufman et al trials, an earlier Phase II trial of single-agent olaparib in a cohort of eight *BRCA*-mutated breast cancer patients reported by Gelmon et al showed no objective responses, although minor tumor regression and disease stabilization were seen. In addition, no objective responses were seen in 15 TNBC patients lacking *BRCA* mutations. The apparent discrepancy in response rates between these trials has not been adequately explained, although the heterogeneity of TNBC and *BRCA* mutations may be a factor, and the lack of clinical response in the TNBC cohort is in contrast to in vitro data with *BRCA* wild-type TNBC cell lines, in which olaparib displayed significant antiproliferative and cytotoxic activity. Clinical trials are planned with olaparib in metastatic *BRCA*-mutated breast cancer as a single agent in comparison to physician choice, without specificity for the TNBC subtype. However, trials with olaparib in early stage breast cancer in both the adjuvant and neoadjuvant settings, given concurrently with or following chemotherapy, have specified not only *BRCA* mutation but also TNBC as entry criteria. In this trial design, both the potential for synthetic lethality as well as chemosensitization are being studied.

**Veliparib**

Veliparib, also known as ABT-888, has had extensive clinical testing in breast cancer, although almost entirely in combination with cytotoxic chemotherapy, and thus acting as a chemosensitizer rather than seeking to induce synthetic lethality in the setting of *BRCA* mutation. Veliparib has been well tolerated when combined with cytotoxic agents at full dose, unlike most other PARP inhibitors, and this is thought to be due the lack of significant PARP trapping, with probable lesser potency as a single agent. Data in cell lines derived from TNBC indicated diminished potency of veliparib in combination with cisplatin, in comparison to olaparib and rucaparib. However, the combination of veliparib with the alkylating agent temozolomide in a tumor xenograft model utilizing a variety of tumors (including breast cancer) showed considerable antimitastic effect, even in tumors resistant to temozolomide alone. Other chemotherapy partners for
veliparib, such as metronomic cyclophosphamide, also appear to be promising, based on Phase I data. The veliparib/temozolomide regimen was taken into a Phase II clinical trial in metastatic breast cancer, with results presenting data in abstract form on 41 patients, including 15 with TNBC. Responses were seen, although primarily in BRCA-mutation carriers. A larger Phase II trial in metastatic breast cancer, limited to BRCA carriers only, was then undertaken with this regimen as one arm of a three-arm trial, with the other arms being veliparib in combination with carboplatin and paclitaxel, and carboplatin/paclitaxel alone. The results of this trial are not yet available, but will not answer the question of the utility of veliparib in TNBC without BRCA mutation. However, a 71-patient neoadjuvant trial, adding the combination of veliparib plus carboplatin to standard neoadjuvant chemotherapy, included 38 women with TNBC and was presented at the 2013 San Antonio Breast Cancer Symposium. A pCR rate of 52% was seen with the veliparib/platinum combination versus 26% in the control arm in this exploratory study in the I-SPY network. A 300-patient neoadjuvant trial, including 17 breast cancers, was reported in abstract form in 2011, with an overall clinical benefit rate of 32% and an overall response rate of 5%. (The frequency of TNBC was not reported.) Veliparib is now under development in BRCA-mutated cancers.

**Niraparib**

Niraparib, also known as MK4827, is a catalytic site inhibitor of PARP-1 and -2 activity, and has PARP-trapping activity as well, exceeding that of olaparib and veliparib. Niraparib showed significant single-agent activity in a Phase I trial in a cohort of 100 patients with various tumor types, including 29 BRCA-mutation carriers. Twelve breast cancer patients were included in this trial, and two of four BRCA carriers with breast cancer showed responses, in addition to two non-BRCA carriers with stable disease. (The breast cancer molecular subtype was not reported). The reported response rate as a single agent in BRCA-mutated cancers was between 40% and 50%. An international Phase III trial in metastatic BRCA-mutated breast cancer, not limited to TNBC, is under way with single-agent niraparib versus physician choice of single-agent standard chemotherapy.

**Rucaparib**

Rucaparib, also known as AG-014699 and PF-01367338, has similar PARP catalytic inhibitory activity to olaparib and niraparib, as well as similar PARP-trapping activity. Rucaparib displayed in vitro cytotoxicity to TNBC cell lines superior to olaparib and veliparib, and in a separate study showed preferential in vitro cytotoxicity to cell lines homozygous for BRCA1 or BRCA2 mutation, either by germ-line loss or somatic methylation. A Phase II study in BRCA-mutated cancers, including 17 breast cancers, was reported in abstract form in 2011, with an overall clinical benefit rate of 32% and an overall response rate of 5%. (The frequency of TNBC was not reported.) Rucaparib is now under development in BRCA-mutated cancers.

**BMN-673**

BMN-673 also has both catalytic PARP-inhibition and PARP-trapping activity; however, the PARP-trapping potency has been reported to be 100-fold greater than that of olaparib. In vitro and in a human mammary xenograft model, BMN 673 targeted tumor cells with mutations in BRCA1, BRCA2 (and PTEN) with greater potency than other PARP inhibitors. Initial clinical results with this compound as a single agent in Phase I were reported in 2013. In a cohort of 39 patients, eight breast cancer patients were included (six with BRCA mutations), with responses seen in two of the mutation carriers. A Phase III trial is underway in metastatic BRCA-mutated breast cancer. It is unclear whether the increased PARP-trapping activity and in vitro potency relative to existing PARP inhibitors will translate into differing clinical activity and/or toxicity. Table 2 summarizes the

<table>
<thead>
<tr>
<th>PARP inhibitor</th>
<th>Trial</th>
<th>Breast cancer (n)</th>
<th>TNBC (n)</th>
<th>BRCA-mutation status</th>
<th>Clinical benefit (CR, PR, or SD)</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Olaparib</td>
<td>Phase I</td>
<td>9</td>
<td>NA</td>
<td>3/9 mutation&lt;sup&gt;+&lt;/sup&gt;</td>
<td>2/3 BRCA&lt;sup&gt;+&lt;/sup&gt; responses (PR and CR)</td>
<td>43</td>
</tr>
<tr>
<td>Olaparib</td>
<td>Phase II</td>
<td>54</td>
<td>29</td>
<td>54 mutation&lt;sup&gt;+&lt;/sup&gt;</td>
<td>11/29 PR, 11/29 SD</td>
<td>45</td>
</tr>
<tr>
<td>Olaparib</td>
<td>Phase II</td>
<td>62</td>
<td>NA</td>
<td>62 mutation&lt;sup&gt;+&lt;/sup&gt;</td>
<td>8/62 PR, 29/62 SD</td>
<td>46</td>
</tr>
<tr>
<td>Olaparib</td>
<td>Phase II</td>
<td>15</td>
<td>15</td>
<td>15 wild type</td>
<td>0/15</td>
<td>48</td>
</tr>
<tr>
<td>Niraparib</td>
<td>Phase I</td>
<td>12</td>
<td>NA</td>
<td>4 mutation&lt;sup&gt;+&lt;/sup&gt;</td>
<td>2/4 BRCA&lt;sup&gt;+&lt;/sup&gt; PR, 2 BRCA wild type SD</td>
<td>54</td>
</tr>
<tr>
<td>Rucaparib</td>
<td>Phase II</td>
<td>17</td>
<td>NA</td>
<td>17 mutation&lt;sup&gt;+&lt;/sup&gt;</td>
<td>5% ORR, 28% SD (entire cohort; breast response not specified)</td>
<td>58</td>
</tr>
<tr>
<td>BMN 673</td>
<td>Phase I</td>
<td>8</td>
<td>NA</td>
<td>6 mutation&lt;sup&gt;+&lt;/sup&gt;</td>
<td>2/6 BRCA&lt;sup&gt;+&lt;/sup&gt; with PR</td>
<td>57</td>
</tr>
</tbody>
</table>

**Abbreviations:** PARP, poly(adenosine triphosphate-ribose) polymerase; TNBC, triple-negative breast cancer; CR, complete response; PR, partial response; SD, stable disease; NA, not available; ORR, overall response rate (CR + PR).
results of single-agent PARP-inhibitor therapy in metastatic breast cancer.

Targeting TNBC with PARP inhibitors: biomarkers of HRD and beyond

It is clear that the majority of responses seen in TNBC treated with PARP inhibitors have been in association with *BRCA* germ-line mutations, with the assumption that a somatic event, such as loss of heterozygosity, methylation silencing, or inactivating mutation, in the wild-type allele has rendered the malignant cells homozygous deficient for either *BRCA1* or *BRCA2*, with the resulting profound defect in HR. Therefore, clinical trials are under way in the adjuvant, neoadjuvant, and metastatic setting for *BRCA*-mutated TNBC. In this patient cohort, the presence of a germ-line *BRCA* mutation is assumed to be the primary predictive biomarker of response to PARP inhibition, and the TNBC subset has been selected, in large part, due to the absence of targeted therapies with evidence of efficacy in this cohort of breast cancer. However, with only a minority of TNBC harboring germ-line *BRCA* mutations, efforts to identify other biomarkers of potential sensitivity to PARP inhibition in the remaining, broader TNBC population have been undertaken. Of these, the most significant has been the search for other biomarkers of HRD in TNBC.

The high degree of genomic instability observed in TNBC without germ-line *BRCA* mutation has suggested the presence of other germ-line or somatically acquired defects in DNA-repair proficiency, and has encouraged the search for biomarkers indicative of HRD. The loss of the highly accurate HR process for double-strand breaks, and its replacement by error-prone pathways, such as nonhomologous end joining, is thought to leave a specific array of genomic defects, a characteristic “genomic scar” for which a biomarker assay may be found. A biomarker of HRD could then be used as a predictive biomarker for responsiveness to chemotherapy known to produce double-stranded DNA breaks, such as platinum agents and alkylating agents, or more importantly to PARP inhibitors.

One approach to the detection of HRD in tumors has been to study the expression levels of DNA-repair genes and pathways, either by mRNA or proteomics and from such studies, specific genes, such as *RECQL4*, as well as *RAD51* and *Ku80*, have been used to predict sensitivity to DNA-damaging chemotherapy and PARP inhibitors. Beyond specific repair genes, a genome-wide transcriptome of HR has recently been reported. However, such expression-based biomarkers do not include an assessment of the extent of the characteristic genomic scar, the functional consequence of HRD. An HRD score, derived from determining the extent of loss of heterozygosity of DNA regions spanning lengths between 15 Mb and whole chromosomes, using single-nucleotide polymorphism analysis, was applied to a cohort of 55 primarily TNBC patients treated with platinum-based neoadjuvant therapy, 13 of whom carried germ-line *BRCA* mutations. The HRD score correlated with the likelihood of pathologic response more accurately than the presence of a *BRCA* mutation, and a number of non-germ-line TNBCs showed high HRD scores and pCR. A biomarker that combines both HRD-associated gene-expression levels, as well as assessment of HRD-specific DNA damage, would likely be beneficial in identifying TNBC (and other tumors) lacking germ-line *BRCA* mutation, but harboring HRD due to other defects. Such a biomarker may then be predictive of sensitivity to PARP inhibition and synthetic lethality.

Beyond *BRCA* and related DNA-repair genes, a number of other genes have been identified that may affect sensitivity to PARP inhibition in tumors with wild-type *BRCA*. PTEN loss has been identified as enhancing sensitivity to PARP inhibition, possibly through the effects on *BRCA* expression, and PARP inhibitors have had clinical activity in tumors with wild-type *BRCA* and loss of PTEN. Mutations in *PTEN*, *PI3K*, *AKT*, *INPP4B*, and other members of the PI3K pathway appear to occur in a substantial proportion of TNBCs. Importantly, specific inhibition of PI3K has been shown to impair *BRCA1* and *BRCA2* expression, and sensitize *BRCA*-proficient TNBC in a patient-derived xenograft model. Such studies have led to a Phase I trial utilizing a PI3K inhibitor in combination with olaparib in TNBC, both *BRCA*-mutated and wild type, with preliminary results in ten TNBC patients reported in June 2014. While an overall response rate of 30% was seen (three of ten TNBC patients), nearly all carried germ-line *BRCA* mutations, raising the question as to whether the responses may have been due to PARP inhibition alone. If this combined approach proves successful in non-*BRCA*-mutated TNBC, another mechanism of inducing synthetic lethality, by combining PARP inhibition and PI3K-pathway blockade, may be identified.

Other instances of mutations causing synthetic lethality with PARP inhibition in *BRCA*-proficient tumors have been identified through in vitro studies, including loss of CDK1, required for the phosphorylation of *BRCA1* in the damage response; loss of the cohesin complex, responsible for the stability of replication forks and necessary for HR in G2; and, in the case of activating *EGFR* mutations, dual inhibition...
of EGFR and PARP.70 It will be important to determine whether these varied genetic lesions will ultimately result in some form of HRD, and will therefore be detected by a more general HRD biomarker, or whether individual biomarkers for each mutation will be needed to confirm their potential for synergy with PARP inhibition.

**Summary**

PARP inhibitors have shown significant clinical activity, particularly as single agents, in tumors harboring defects in double-strand DNA-break repair, the best studied being ovarian and breast cancers with BRCA germ-line mutations, in which they have induced synthetic lethality. Several PARP inhibitors are in Phase III clinical trials, and it is likely that a PARP inhibitor will be approved for clinical use in BRCA-mutated ovarian cancer in 2014. Although in vitro measures of potency show wide variation in PARP catalytic inhibition and PARP trapping at the DNA-binding site, such differences have yet to show clinical relevance.

In TNBC, a significant minority are due to BRCA germ-line mutations, and this cohort will likely benefit from therapy with a PARP inhibitor in the metastatic setting, as well as ultimately in adjuvant and neoadjuvant therapy. Several large, international trials are under way in 2014 in TNBC with BRCA germ-line mutations. The majority of TNBCs, however, have wild-type BRCA1 and BRCA2, yet within this group, a subset may have intrinsic HRD due to other causes, and strong evidence exists to suggest this is the case. Predictive biomarkers for the detection of clinically significant HRD are under development and nearing clinical application, and will be essential for identifying the broader TNBC cohort that may benefit from PARP-inhibitor therapy. In addition, a number of related pathways, ultimately converging on DNA repair, appear promising as additional opportunities for PARP inhibition, either by mutation-based or targeted therapy-induced synthetic lethality with PARP inhibition. It is clear that the classification of this subset of breast cancer as simply “triple negative” is entirely inadequate for the appropriate application of this promising new class of therapeutic molecules, and will soon be replaced by a more biologically accurate set of biomarkers, particularly those that define defects in DNA repair.

**Disclosure**

The author has served as a consultant to Tesaro and Myriad Genetics.

**References**